Atara Biotherapeutics, Inc. · NASDAQ:ATRA
Atara Biotherapeutics — H.C. Wainwright 26th Annual Global Investment Conference (September 2024)
22 slides from Atara Biotherapeutics's conference presentation, Sep 9, 2024
Slide 1: Unleashing the Promise of Cell Therapy for Cancer and Autoimmune Diseases
UNLEASHING THE PROMISE OF CELL THERAPY FOR CANCER AND AUTOIMMUNE DISEASES SEP 9, 2024 Nasdaq: ATRA 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prese
Slide 3: Atara Biotherapeutics is Focused on Natural T-Cell Biology with a Differentiated, Off-the-Shelf Approach
Atara Biotherapeutics is Focused on Natural T-Cell Biology with a Differentiated, Off-the-Shelf Approach Atara Overview Atara’s Allogeneic CAR T Programs • Company founded in 2012 B-cell Driven Autoimmune Diseases • Headquartered in Thousand Oaks, CA Hematological Malignancies with ~165 employees AT
Slide 4: Innovating Next-Gen CAR T Leveraging the Only Allogeneic T-cell Platform With an Approved Product
Innovating Next-Gen CAR T Leveraging the Only Allogeneic T-cell Platform With an Approved Product Allogeneic EBV T-Cell (EBVALLOTM) Next-gen Allogeneic CAR T EBV TCR Chimeric Antigen Receptor CAR EBV TCR Manufacturing Viral Vector Healthy Donor Cells EBV T Cell EBV CAR T Cell No gene editing of th
Slide 5: Atara's Allogeneic CAR-T Manufacturing Process Leverages Our Commercial Manufacturing Process for Tab-cel
Atara’s Allogeneic CAR-T Manufacturing Process Leverages Our Commercial Manufacturing Process for Tab-cel 1 2 3 4 Expose B cells to Expose Transduce EBV- Store EBV to produce donor specific T cells CAR T vials EBV-presenting T cells to with CAR viral in inventory B cells (BLCL) BLCLs vector Healthy
Slide 6: Atara's Allogeneic CAR T Platform Designed to Improve Patient Journey and Expand Access Versus Autologous Cell Therapies
Atara’s Allogeneic CAR T Platform Designed to Improve Patient Journey and Expand Access Versus Autologous Cell Therapies Current Autologous CAR T Patient Journey Apheresis Lymphodepletion CAR T Treatment Post Infusion Monitoring • Time consuming, extra • Chemotherapy side effects • 2-5 weeks-long pr
Slide 7: Allogeneic Requires a Different Approach to Overcome Key Challenges
Allogeneic Requires a Different Approach to Overcome Key Challenges Conventional αβ CAR T Atara’s CAR Platform Key Challenges to Overcome • Graft vs Host Disease and Allorejection: TCR MHC Requires genetic alterations to TCR and MHC. Deletion of MHC also increases NK-cell- mediated CAR-T destruction
Slide 8: Atara's CAR T Platform Combines the Natural Biology of T Cells With the Benefits of an Allogeneic Therapy
Atara’s CAR T Platform Combines the Natural Biology of T Cells With the Benefits of an Allogeneic Therapy Atara’sAtara’s Allogeneic CAR T Platform CAR Platform ATA3219 Key Features EBV Graft vs Host Disease (GvHD) and Allorejection: Specificity Retained Retained 2 3 1• Retained TCR: Unedited TCR ser
Slide 9: Clinical CAR T Data From Industry Leaders and Academia Reinforce Key Features of Atara's CAR T Platform
Clinical CAR T Data From Industry Leaders and Academia Reinforce Key Features of Atara’s CAR T Platform in Oncology and Autoimmune Diseases EBV Specific TCR & Less Differentiated 1XX Costimulatory Retained MHC with Phenotype Domain Partial HLA Matching Durability and potency Expansion, persistence S
Slide 10: ATA3219 in NHL: Opportunity To Compete With a Differentiated Profile Given Limitations With Other CD19-Targeted Therapies
ATA3219 in NHL: Opportunity To Compete With a Differentiated Profile Given Limitations With Other CD19-Targeted Therapies Unmet Need Despite Approved Auto CAR T Bispecifics & Allo CAR Yet to Deliver Access challenges for Efficacy and safety auto CAR T challenges for bispecifics Only ~20-40% of eligi
Slide 11: ATA3219 in NHL: Potential Best-in-Class Profile with Superior In Vivo Persistence & Efficacy
ATA3219 in NHL: Potential "Best-in-Class" Profile with Superior In Vivo Persistence & Efficacy Versus Commercial Auto CD19 CAR T Benchmark Less Differentiated ATA3219 Longer Persistence ATA3219 Superior Efficacy T Cells for ATA3219 versus auto CD19 CAR benchmark1 versus auto CD19 CAR benchmark1 CD19
Slide 12: SLE: High Unmet Need and Opportunity for CAR T Therapy
SLE: High Unmet Need and Opportunity for CAR T Therapy High Unmet Need in Systemic Lupus Erythematosus (SLE) • SLE is a chronic autoimmune inflammatory disease affecting multiple organs, with heterogeneity of clinical symptoms and disease severity making it difficult to treat1 • Unmet needs include
Slide 13: The Goal of CAR T Mediated B-Cell Depletion Is Drug-Free and Long-Term Responses for SLE Patients
The Goal of CAR T Mediated B-Cell Depletion Is Drug-Free and Long-Term Responses for SLE Patients CAR T penetrates deep into tissues and rapidly depletes B- cell depletion pathogenic CD19+ B cells Immunological “reset” and reconstitution of naïve B cells Immune system reconstitution lacking the auto
Slide 14: ATA3219 Is Designed to Have a Best-in-Class CAR T Profile in Multiple Autoimmune Diseases
ATA3219 Is Designed to Have a Best-in-Class CAR T Profile in Multiple Autoimmune Diseases Atara’s Differentiated Potential for Enhanced Efficacy, Allogeneic T-Cell Platform Tolerability and Patient Access IFN-ᵞ TNF-ἀ IL-6 • Partial HLA matching • Off-the-shelf availability 120000 12000 400 simplifie
Slide 15: ATA3219 Maintains Comparable Cytotoxic Function With Reduced Inflammatory Cytokine Release Compared to Autologous Benchmark
ATA3219 Maintains Comparable Cytotoxic Function With Reduced Inflammatory Cytokine Release Compared to Autologous Benchmark 100 120 % Cytolysis 80 Cell phenotype 100 Terminal Effector (CD45RO-, CCR7-) %Nalm-6 Cytolysis 60 80 Effector Memory % of CD3 (CD45RO+, CCR7-) CD19-specific 40 Maintained a 60
Slide 16: Rationale for No Lymphodepletion in Extrarenal SLE Cohort
Rationale for No Lymphodepletion in Extrarenal SLE Cohort EBV T Cell Partial HLA Matching Additional Features • αβ T-cell: Same T-cell type as proven • Retained MHC: Partial HLA matching • 1XX costimulatory domain: commercial autologous CAR Ts limits host versus graft rejection5 Optimizes potency an
Slide 17: ATA3431: Off-the-Shelf Allogeneic CD19/CD20 CAR T Program Progressing Toward IND Submission in H2 2025
ATA3431: Off-the-Shelf Allogeneic CD19/CD20 CAR T Program Progressing Toward IND Submission in H2 2025 Targeting CD19 and CD20 reduces probability of relapse due to Retained CD19 antigen loss, hypothesized to be a major cause of treatment MHC resistance or disease relapse after CD19 CAR T treatment
Slide 18: ATA3431: Compelling Proof-of-Concept and Competitive Profile
ATA3431: Compelling Proof-of-Concept and Competitive Profile Greater Anti-Tumor Efficacy vs CD19/CD20 Autologous Benchmark Challenging CD19low / CD20+ Raji model 10 10 ATA3431 100 Tumor Burden (BLI; photon/s) Auto benchmark NTD 10 9 PBS Percent Survival 10 8 50 10 7 10 6 10 5 0 10 20 30 40 50 60 70
Slide 19: Differentiated Allogeneic T-Cell Immunotherapy Pipeline
Differentiated Allogeneic T-Cell Immunotherapy Pipeline Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Registration Next Milestone ATA3219 Q1 2025: Initial NHL Ph 1 Non-Hodgkin’s Lymphoma (NHL) CD19 (Oncology) clinical data expected Lupus Nephritis (LN) Mid-2025: Initial LN Ph 1 clini
Slide 20: Expanded Global Tab-cel Partnership With Pierre Fabre Laboratories
Expanded Global Tab-cel® Partnership With Pierre Fabre Laboratories Pierre Fabre Laboratories license for Atara received ~$27M following tab-cel global development, closing and $20M following the manufacturing and commercialization, positive pre-BLA meeting. Atara also with up to $640M in potential
Slide 21: Tab-cel BLA Accepted With Priority Review and a PDUFA Target Action Date of January 15, 2025
Tab-cel BLA Accepted With Priority Review and a PDUFA Target Action Date of January 15, 2025 The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases • The latest pivotal ALLELE study data demonstrated a statis
Slide 22: Thank You
THANK YOU Nasdaq: ATRA ATARA BIO